Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38055253

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2023 Dec 7
First author
Moore KN

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Moore KN
      type
      Author
    2. name
      Angelergues A
      type
      Author
    3. name
      Konecny GE
      type
      Author
    4. name
      García Y
      type
      Author
    5. name
      Banerjee S
      type
      Author
    6. name
      Lorusso D
      type
      Author
    7. name
      Lee JY
      type
      Author
    8. name
      Moroney JW
      type
      Author
    9. name
      Colombo N
      type
      Author
    10. name
      Roszak A
      type
      Author
    11. name
      Tromp J
      type
      Author
    12. name
      Myers T
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Moore KN
      type
      Author
    2. name
      Angelergues A
      type
      Author
    3. name
      Konecny GE
      type
      Author
    4. name
      García Y
      type
      Author
    5. name
      Banerjee S
      type
      Author
    6. name
      Lorusso D
      type
      Author
    7. name
      Lee JY
      type
      Author
    8. name
      Moroney JW
      type
      Author
    9. name
      Colombo N
      type
      Author
    10. name
      Roszak A
      type
      Author
    11. name
      Tromp J
      type
      Author
    12. name
      Myers T
      type
      Author
    bibliography ids
    1. nci-bib-dc715865e7778bd5bd1eb5f3
    book metadata
    content sha256
    3b5df5d22a272984a6b68f53e0dcedae2c82f1b9860bf82d7cc6b060e339560c
    document type
    citation
    dois
    1. 10.1056/NEJMoa2309169
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:38055253
    immutable id
    pubmed:38055253@3b5df5d22a272984a6b68f53e0dcedae2c82f1b9860bf82d7cc6b060e339560c
    journal
    abbreviation
    N Engl J Med
    issn electronic
    1533-4406
    issn print
    0028-4793
    issue
    23
    name
    The New England journal of medicine
    nlm unique id
    0255562
    pages
    2162-2174
    volume
    389
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      38055253
      provenance
      batch id
      6d213eecf21b6b7867cb
      provider
      NCBI PubMed ESummary
      record sha256
      0a1e8ae5ee0f3379cdd2b31e58fba8fa76a2cf5686e8b67dc609cea116c2c79b
      response sha256
      684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
      retrieved at
      2026-09-09T23:48:19.049083+00:00
      publication date
      display
      2023 Dec 7
      precision
      day
      year
      2023
      publication types
      1. Clinical Trial, Phase III
      2. Comparative Study
      3. Journal Article
      4. Randomized Controlled Trial
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/38055253/
      title
      Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

      Preserved source evidence · Not medical advice